Cargando…
Significantly Increased Patient Satisfaction Following Liquid Formulation AbobotulinumtoxinA Treatment in Glabellar Lines: FACE-Q Outcomes From a Phase 3 Clinical Trial
BACKGROUND: The FACE-Q patient-reported outcome assesses patient experiences/outcomes with aesthetic facial procedure. A recent trial of abobotulinumtoxinA (ASI, liquid formulation) was the first to our knowledge to assess satisfaction with FACE-Q after glabellar line (GL) injection. OBJECTIVES: The...
Autores principales: | Ascher, Benjamin, Rzany, Berthold, Kestemont, Philippe, Hilton, Said, Heckmann, Marc, Bodokh, Isaac, Noah, Ernst Magnus, Boineau, Dominique, Kerscher, Martina, Volteau, Magali, Le Berre, Philippe, Picaut, Philippe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427150/ https://www.ncbi.nlm.nih.gov/pubmed/31550352 http://dx.doi.org/10.1093/asj/sjz248 |
Ejemplares similares
-
Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar Lines
por: Ascher, Benjamin, et al.
Publicado: (2019) -
Corrigendum to: Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar Lines
por: Ascher, Benjamin, et al.
Publicado: (2021) -
Response to “Facial Line Outcomes (FLO-11) and Facial Line Satisfaction Questionnaire (FLSQ) Meet FDA PRO Guidance”
por: Ascher, Benjamin, et al.
Publicado: (2020) -
Liquid AbobotulinumtoxinA: Pooled Data From Two Double-Blind, Randomized, Placebo-Controlled Phase III Studies of Glabellar Line Treatment
por: Hilton, Said, et al.
Publicado: (2022) -
Long-term Efficacy and Safety of Liquid AbobotulinumtoxinA Formulation for Moderate-to-Severe Glabellar Lines: A Phase III, Double-Blind, Randomized, Placebo-Controlled and Open-Label Study
por: Kestemont, Philippe, et al.
Publicado: (2021)